These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Gallium-68 PET: a new frontier in receptor cancer imaging. Al-Nahhas A; Win Z; Szyszko T; Singh A; Nanni C; Fanti S; Rubello D Anticancer Res; 2007; 27(6B):4087-94. PubMed ID: 18225576 [TBL] [Abstract][Full Text] [Related]
7. Clinical applications of 68Ga-DOTANOC in neuroendocrine tumours. Lopci E; Nanni C; Rampin L; Rubello D; Fanti S Minerva Endocrinol; 2008 Sep; 33(3):277-81. PubMed ID: 18846030 [TBL] [Abstract][Full Text] [Related]
8. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer. Giovacchini G; Giovannini E; Riondato M; Ciarmiello A Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291 [TBL] [Abstract][Full Text] [Related]
9. [Diagnosis, staging and follow-up of neuroendocrine tumors: role of somatostatin receptors scintigraphy]. Lebtahi R Ann Pathol; 2011 Nov; 31(5 Suppl):S83-4. PubMed ID: 22054471 [No Abstract] [Full Text] [Related]
11. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors. Fani M; Mueller A; Tamma ML; Nicolas G; Rink HR; Cescato R; Reubi JC; Maecke HR J Nucl Med; 2010 Nov; 51(11):1771-9. PubMed ID: 20956465 [TBL] [Abstract][Full Text] [Related]
12. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview. Warner RR; O'dorisio TM Semin Nucl Med; 2002 Apr; 32(2):79-83. PubMed ID: 11965602 [TBL] [Abstract][Full Text] [Related]
13. Factor analysis of dynamic series (FADS) in somatostatin receptor imaging. Kolesnikov-Gauthier H; Huglo D; Nocaudie M; Marchandise X J Nucl Med; 1999 Jan; 40(1):33-9. PubMed ID: 9935053 [TBL] [Abstract][Full Text] [Related]
14. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas]. Banzo J; Abós MD; Prats E; García F; Razola P Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088 [No Abstract] [Full Text] [Related]
15. Contemporary nuclear medicine imaging of neuroendocrine tumours. Wong KK; Waterfield RT; Marzola MC; Scarsbrook AF; Chowdhury FU; Gross MD; Rubello D Clin Radiol; 2012 Nov; 67(11):1035-50. PubMed ID: 22633086 [TBL] [Abstract][Full Text] [Related]
16. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519 [TBL] [Abstract][Full Text] [Related]
18. The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuro-endocrine tumors. Shapiro B; Sisson JC; Shulkin BL; Gross MD; Zempel S Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):3-8. PubMed ID: 9002740 [TBL] [Abstract][Full Text] [Related]
19. 110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET. Lubberink M; Tolmachev V; Widström C; Bruskin A; Lundqvist H; Westlin JE J Nucl Med; 2002 Oct; 43(10):1391-7. PubMed ID: 12368379 [TBL] [Abstract][Full Text] [Related]
20. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. Baudin E; Lumbroso J; Schlumberger M; Leclere J; Giammarile F; Gardet P; Roche A; Travagli JP; Parmentier C J Nucl Med; 1996 Jun; 37(6):912-6. PubMed ID: 8683310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]